Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients

Choe, Pyoeng Gyun; Kang, Chang Kyung; Suh, Hyeon Jeong; Jung, Jongtak; Kang, EunKyo; Lee, Sun Young; Song, Kyoung-Ho; Kim, Hong Bin; Kim, Nam Joong; Park, Wan Beom; Kim, Eu Suk; Oh, Myoung‐don

doi:10.3201/eid2610.202211

Cited by 66 publications

(53 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our cohort, children were more likely to be exposed to SARS-CoV-2 in the home due to fact that their parent(s) worked in healthcare. The findings from this study may therefore provide a greater insight into how younger children react when exposed to SARS- There is evidence from adult serological studies that those with severe illness develop a significantly greater antibody response than those with mild or asymptomatic disease (31)(32)(33).…”

Section: Discussionmentioning

confidence: 88%

Seroprevalence of SARS-CoV-2 antibodies in children - A prospective multicentre cohort study

Waterfield

Watson

Moore

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Studies based on molecular testing of oral/nasal swabs underestimate SARS-CoV-2 infection due to issues with test sensitivity and timing of testing. The objective of this study was to report the presence of SARS-CoV-2 antibodies, consistent with previous infection, and to report the symptomatology of infection in children. Design This multicentre observational cohort study, conducted between 16th April - 3rd July 2020 at 5 UK sites, aimed to recruit 900 children aged 2 to 15 years of age. Participants provided blood samples for SARS-CoV-2 antibody testing and data were gathered regarding unwell contacts and symptoms. Results 1007 participants were enrolled, and 992 were included in the final analysis. The median age of participants was 10.1 years. There were 68 (6.9%) participants with positive SARS-CoV-2 antibody tests indicative of previous SARS-CoV-2 infection. Of these, 34/68 (50%) reported no symptoms. The presence of antibodies and the mean antibody titre was not influenced by age. Following multivariate analysis 4 independent variables were identified as significantly associated with SARS-CoV-2 infection. These were: known infected household contact; fatigue; gastrointestinal symptoms; and changes in sense of smell or taste. Discussion In this study children demonstrated similar antibody titres in response to SARS-CoV-2 irrespective of age. The symptoms of SARS-CoV-2 infection in children were subtle but of those reported, fatigue, gastrointestinal symptoms and changes in sense of smell or taste were most strongly associated with antibody positivity. Registration This study was registered at https://www.clinicaltrials.gov (trial registration: NCT04347408) on the 15/04/2020.

show abstract

Section: Discussionmentioning

confidence: 88%

Seroprevalence of SARS-CoV-2 antibodies in children - A prospective multicentre cohort study

Waterfield

Watson

Moore

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…There is evidence from adult serological studies that those with severe illness develop a significantly greater antibody response than those with mild or asymptomatic disease. 28–30 This has raised concerns that children, who typically have mild disease, may fail to develop a meaningful antibody response to SARS-CoV-2 infection. More recently, emerging adult data suggest that even asymptomatic adults are capable of mounting a potentially lasting and protective immune response.…”

Section: Discussionmentioning

confidence: 99%

Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study

et al. 2020

View full text Add to dashboard Cite

BackgroundStudies based on molecular testing of oral/nasal swabs underestimate SARS-CoV-2 infection due to issues with test sensitivity, test timing and selection bias. The objective of this study was to report the presence of SARS-CoV-2 antibodies, consistent with previous infection.DesignThis multicentre observational cohort study, conducted between 16 April to 3 July 2020 at 5 UK sites, recruited children of healthcare workers, aged 2–15 years. Participants provided blood samples for SARS-CoV-2 antibody testing and data were gathered regarding unwell contacts and symptoms.Results1007 participants were enrolled, and 992 were included in the final analysis. The median age of participants was 10·1 years. There were 68 (6.9%) participants with positive SARS-CoV-2 antibody tests indicative of previous SARS-CoV-2 infection. Of these, 34/68 (50%) reported no symptoms prior to testing. The presence of antibodies and the mean antibody titre was not influenced by age. Following multivariable analysis four independent variables were identified as significantly associated with SARS-CoV-2 seropositivity: known infected household contact OR=10.9 (95% CI 6.1 to 19.6); fatigue OR=16.8 (95% CI 5.5 to 51.9); gastrointestinal symptoms OR=6.6 (95% CI 3.0 to 13.8); and changes in sense of smell or taste OR=10.0 (95% CI 2.4 to 11.4).DiscussionChildren demonstrated similar antibody titres in response to SARS-CoV-2 irrespective of age. Fatigue, gastrointestinal symptoms and changes in sense of smell or taste were the symptoms most strongly associated with SARS-CoV-2 antibody positivity.Trial registration numberNCT0434740.

show abstract

“…Neutralising antibody responses correlated with disease severity in all studies in which this association was tested. 7,43,49,66,76,85,87,[96][97][98] Importantly, the few studies that investigated asymptomatic cases found those individuals were considerably less likely to develop detectable serum neutralising antibody responses than cases with symptoms. With regard to age and sex, evidence was mixed and a limitation across all papers was a lack of statistical adjustment for severity.…”

Section: Correlates Of Neutralising Antibody Productionmentioning

confidence: 99%

Antibody response to SARS-CoV-2 infection in humans: a systematic review

Post

Eddy

Huntley

et al. 2020

Preprint

View full text Add to dashboard Cite

Introduction Progress in characterising the humoral immune response to Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) has been rapid but areas of uncertainty persist. This review comprehensively evaluated evidence describing the antibody response to SARS-CoV-2 published from 01/01/2020-26/06/2020. Methods Systematic review. Keyword-structured searches were carried out in MEDLINE, Embase and COVID-19 Primer. Articles were independently screened on title, abstract and full text by two researchers, with arbitration of disagreements. Data were double-extracted into a pre-designed template, and studies critically appraised using a modified version of the MetaQAT tool, with resolution of disagreements by consensus. Findings were narratively synthesised. Results 150 papers were included. Most studies (75%) were observational in design, and included papers were generally of moderate quality based on hospitalised patients. Few considered mild or asymptomatic infection. Antibody dynamics were well described in the acute phase, and up to around 3 months from disease onset, although inconsistencies remain concerning clinical correlates. Development of neutralising antibodies following SARS-CoV-2 infection is typical, although titres may be low. Specific and potent neutralising antibodies have been isolated from convalescent plasma. Cross reactivity but limited cross neutralisation occurs with other HCoVs. Evidence for protective immunity in vivo is limited to small, short-term animal studies, which show promising initial results in the immediate recovery phase. Interpretation Published literature on immune responses to SARS-CoV-2 is of variable quality with considerable heterogeneity with regard to methods, study participants, outcomes measured and assays used. Antibody dynamics have been evaluated thoroughly in the acute phase but longer follow up and a comprehensive assessment of the role of demographic characteristics and disease severity is needed. The role of protective neutralising antibodies is emerging, with implications for therapeutics and vaccines. Large, cross-national cohort studies using appropriate statistical analysis and standardised serological assays and clinical classifications should be prioritised.

show abstract

Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients

Cited by 66 publications

References 9 publications

Seroprevalence of SARS-CoV-2 antibodies in children - A prospective multicentre cohort study

Seroprevalence of SARS-CoV-2 antibodies in children - A prospective multicentre cohort study

Seroprevalence of SARS-CoV-2 antibodies in children: a prospective multicentre cohort study

Antibody response to SARS-CoV-2 infection in humans: a systematic review

Contact Info

Product

Resources

About